Intech Investment Management LLC Grows Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Intech Investment Management LLC raised its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 120.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 81,055 shares of the company’s stock after buying an additional 44,208 shares during the quarter. Intech Investment Management LLC’s holdings in Amneal Pharmaceuticals were worth $642,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Victory Capital Management Inc. raised its stake in Amneal Pharmaceuticals by 58.7% in the 3rd quarter. Victory Capital Management Inc. now owns 99,215 shares of the company’s stock valued at $825,000 after acquiring an additional 36,700 shares during the period. Quest Partners LLC bought a new stake in shares of Amneal Pharmaceuticals in the third quarter valued at approximately $84,000. Charles Schwab Investment Management Inc. raised its position in shares of Amneal Pharmaceuticals by 16.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,404,883 shares of the company’s stock valued at $11,689,000 after purchasing an additional 202,863 shares during the period. Quantbot Technologies LP boosted its holdings in Amneal Pharmaceuticals by 274.8% in the 3rd quarter. Quantbot Technologies LP now owns 111,181 shares of the company’s stock worth $925,000 after buying an additional 81,519 shares during the period. Finally, FMR LLC grew its stake in Amneal Pharmaceuticals by 25.9% in the 3rd quarter. FMR LLC now owns 203,510 shares of the company’s stock valued at $1,693,000 after buying an additional 41,882 shares in the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Analysts Set New Price Targets

AMRX has been the topic of several recent research reports. StockNews.com downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 19th. Barclays increased their price objective on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, March 3rd. Finally, JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $9.00 to $12.00 in a report on Monday, February 24th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $10.80.

Amneal Pharmaceuticals Stock Performance

NASDAQ:AMRX opened at $8.66 on Monday. Amneal Pharmaceuticals, Inc. has a 52-week low of $5.18 and a 52-week high of $9.48. The stock has a fifty day moving average of $8.38 and a 200 day moving average of $8.37. The firm has a market capitalization of $2.68 billion, a price-to-earnings ratio of -12.74 and a beta of 1.05.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Friday, February 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). The business had revenue of $730.52 million for the quarter, compared to the consensus estimate of $708.21 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. During the same quarter last year, the business posted $0.14 EPS. Equities analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In other news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the company’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the transaction, the insider now directly owns 48,578,209 shares in the company, valued at approximately $405,628,045.15. This represents a 9.33 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gautam Patel sold 17,410 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $8.01, for a total value of $139,454.10. Following the transaction, the director now directly owns 2,031,476 shares in the company, valued at approximately $16,272,122.76. This represents a 0.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,240,000 shares of company stock valued at $43,754,000 in the last quarter. Insiders own 26.56% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.